Talvey Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, expansion of biologic drug approvals, rising awareness of disease-modifying therapies, improved diagnostic capabilities, growing access to specialty care.

The growth in the forecast period can be attributed to increasing adoption of personalized immunotherapy, rising investments in biosimilar development, expansion of digital patient monitoring tools, growing focus on cost-effective biologic alternatives, increasing long-term treatment adherence initiatives. Major trends in the forecast period include increasing adoption of targeted autoimmune therapies, growing use of biosimilars in chronic disease management, expansion of precision-based treatment protocols, rising focus on long-term disease control, improved patient monitoring and therapy optimization.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Talvey market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues, perceiving them as harmful invaders. The increasing prevalence of these conditions is linked to factors such as genetic predisposition, environmental triggers, lifestyle changes, and greater awareness. Talvey (natalizumab-sztn) is used to treat autoimmune diseases by targeting and blocking integrins, preventing immune cells from entering the central nervous system and reducing inflammation, a key factor in conditions such as multiple sclerosis and Crohn’s disease. For example, in January 2025, the Mayo Clinic reported that around 15 million people are estimated to have one or more of 105 autoimmune diseases. Therefore, the rising frequency of autoimmune illnesses is driving the growth of the Talvey market.

The increase in healthcare expenditure is also expected to propel the growth of the Talvey market. Healthcare expenditure encompasses total spending on medical services, treatments, hospital care, pharmaceuticals, and related health services. Factors driving this increase include an aging population, the growing prevalence of chronic diseases, and rising demand for healthcare services. Higher healthcare spending ensures broader access to treatments such as Talvey and supports affordability for patients who require it. For instance, in November 2025, the OECD reported that in 2024, member countries allocated an average of approximately 9.3% of their GDP to health. Therefore, increasing healthcare expenditure is fueling the growth of the Talvey market.

Major companies in the Talvey market are focusing on obtaining drug approvals to strengthen their competitive position and expand treatment options. Drug approval is the regulatory process in which authorities evaluate a drug’s safety, efficacy, and quality before authorizing its use. For example, in August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson, a US-based company, announced U.S. FDA approval for TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody for adult patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy, including immunomodulatory drugs, anti-CD38 antibodies, and proteasome inhibitors. TALVEY targets the CD3 receptor on T cells and GPRC5D on multiple myeloma cells, non-malignant plasma cells, and keratinized tissues. Administered as weekly or biweekly subcutaneous injections after a step-up phase, TALVEY provides flexible dosing and was approved under accelerated approval based on response rate and durability.

Major companies operating in the talvey market are Johnson & Johnson.

North America was the largest region in the talvey market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the talvey market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the talvey market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the talvey market by increasing costs of imported biologic manufacturing inputs, active pharmaceutical ingredients, specialized excipients, and cold-chain logistics equipment used in biosimilar production and distribution. North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces cost pressure in export-oriented manufacturing. These tariffs are contributing to higher therapy pricing and procurement challenges for healthcare systems. However, they are also encouraging localized biologics manufacturing, regional supply chain strengthening, and investments in domestic biosimilar production capabilities.

The talvey market research report is one of a series of new reports that provides talvey market statistics, including talvey industry global market size, regional shares, competitors with a talvey market share, detailed talvey market segments, market trends and opportunities, and any further data you may need to thrive in the talvey industry. This talvey market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Talvey is a biosimilar medication used to treat certain autoimmune conditions by targeting and inhibiting integrins, proteins that play a role in inflammation and immune cell movement. It is commonly prescribed for conditions such as multiple sclerosis (MS) and Crohn’s disease, helping to reduce inflammation, prevent relapses, and improve overall patient outcomes.

The main formulations of Talvey include 3 mg/1.5 ml and 40 mg/ml. The 3 mg/1.5 ml formulation contains 3 mg of the active ingredient in each 1.5 ml dose. Talvey is used in relapsed or refractory multiple myeloma and for monotherapy treatment. It is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies, and is used by adult and geriatric patients.

The talvey market consists of sales of biosimilars, monoclonal antibodies, corticosteroids, and immunosuppressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.